Using light and occupational therapy to manage fatigue in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of light therapy combined with occupational therapy in reducing cancer-related fatigue (CRF) in patients with genitourinary cancers. Participants are randomized into four groups: one receiving bright white light therapy, another undergoing occupational therapy, a third group receiving both interventions, and a control group receiving standard care. The primary objective is to assess fatigue levels three months post-intervention, while secondary objectives include measuring changes in fatigue and occupational performance. This approach aims to provide a low-burden, evidence-based intervention for managing CRF.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18 and over
* Sufficiently fluent in English
* On active treatment receiving systemic therapy (e.g., chemotherapy, immunotherapy, hormonal therapy, etc.) or radiotherapy
* Patients with diagnosis of a genitourinary (GU) cancer (e.g., prostate, kidney, and bladder cancer) who have grade 1 or 2 fatigue based on physician assessment at the time of study entry
* Clinician assessed prognosis of greater than or equal to six months
* Willing and independently able to provide consent
* Receive a pre-screen FACIT-Fatigue score of less than or equal to 30

Exclusion Criteria:

* Severe sleep disorders (e.g. narcolepsy)
* Eye Diseases which limit the ability of light to be processed (e.g. untreated cataracts, severe glaucoma, macular degeneration, blindness, pupil dilation problems or other retinal disorder)
* Severe psychological impairment (e.g., bipolar disorder or manic episodes)
* Current employment in night shift work
* Previous use of light therapy to alleviate fatigue or depressive symptoms
* Secondary cancer diagnosis within the past 5 years
* Plans to travel across meridians during treatment
* Pregnancy
* Currently recovering from previous eye surgery within the past 6 months that causes eye irritation
* Sensitivity to light, epilepsy, or a history of seizures

Where it's running

• City of Hope Medical Center
  Duarte, California, United States Recruiting

Study contacts

• Principal investigator: William Dale — City of Hope Medical Center

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Vanguard: a new blood test approach to screen for multiple cancers

  This study will test two different blood-based multi-cancer detection tests in adults 45–75 without cancer to see if they find cancers earlier than usual care.

  Recruiting at 46 sites National Cancer Institute (NCI) · Pleasanton, California and 45 other locations · NCT06995898

• Understanding NK Cell Function in Prostate Cancer Across Races

  This study tests whether natural killer (NK) cells behave differently in prostate cancer patients of diverse racial backgrounds by analyzing blood and tissue samples.

  Recruiting Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07910019

• MRI or CT planning to guide high-dose-rate prostate brachytherapy

  This trial tests whether adding an MRI to CT-based treatment planning for HDR prostate brachytherapy changes urinary side effects in men with localized prostate cancer.

  Recruiting at 3 sites Emory University · Atlanta, Georgia and 2 other locations · NCT07859722

• Targeted Early Detection for Men at High Genetic Risk for Prostate Cancer

  This study tests urinary biomarkers and PSA to see if they can improve early detection for men with a strong family or genetic risk for prostate cancer.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07645391

• Urine and MRI approach to find aggressive prostate cancer early

  This study tests whether a urine test called MPS2, paired with MRI, can better detect aggressive prostate cancer in men 50–75 at risk, possibly reducing unnecessary biopsies.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07526545

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.